NRSNNeuroSense Therapeutics Ltd
$0.696
$0.012
(1.70%)
Closed $0.696
$0.00
(0.00%)
After Hours
Mkt Cap$25.03M
Vol107,633.00
NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS"
NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS" NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS" PR Newswire CAMBRIDGE, Mass., July 6, 2026 Featuring renowned ALS expert Prof...
PR Newswire
NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALS
NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALS NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark...
PR Newswire
NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease
NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease PR Newswire CAMBRIDGE, Mass., June 25, 2026 PrimeC was...
PR Newswire
EverythingALS to Host NeuroSense in a Community Event Named: PrimeC - Connecting the Dots
EverythingALS to Host NeuroSense in a Community Event Named: PrimeC - Connecting the Dots EverythingALS to Host NeuroSense in a Community Event Named: PrimeC - Connecting the Dots PR Newswire CAMBRIDGE, Mass., June 22, 2026 CAMBRIDGE, Mass., June 22, 2026 /PRNewswire/ -- NeuroSense Therapeutics...
PR Newswire
NeuroSense Granted South Korean Patent Covering PrimeC Composition for ALS
NeuroSense Granted South Korean Patent Covering PrimeC Composition for ALS NeuroSense Granted South Korean Patent Covering PrimeC Composition for ALS PR Newswire CAMBRIDGE, Mass., June 11, 2026 Patent claims cover PrimeC's proprietary formulation, manufacturing process and use in ALSExpands...
PR Newswire
NeuroSense Therapeutics Receives Japanese Patent Grant for PrimeC Novel Composition
NeuroSense Therapeutics Receives Japanese Patent Grant for PrimeC Novel Composition NeuroSense Therapeutics Receives Japanese Patent Grant for PrimeC Novel Composition PR Newswire CAMBRIDGE, Mass., June 9, 2026 Patent Protection Extends Through 2042 following recent U.S., Australia and Brazil...
PR Newswire
NeuroSense Announces Pricing of Insider-Led PIPE Financing
NeuroSense Announces Pricing of Insider-Led PIPE Financing NeuroSense Announces Pricing of Insider-Led PIPE Financing PR Newswire CAMBRIDGE, Mass., April 28, 2026 Financing led by CEO Alon Ben-Noon...
PR Newswire
NeuroSense Granted Brazilian Patent Covering PrimeC Composition
NeuroSense Granted Brazilian Patent Covering PrimeC Composition NeuroSense Granted Brazilian Patent Covering PrimeC Composition PR Newswire CAMBRIDGE, Mass., April 6, 2026 Patent Protection Through...
PR Newswire
NeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding Minimum Bid Price and Market Value Requirements
NeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding Minimum Bid Price and Market Value Requirements NeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding...
PR Newswire
NeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business Update
NeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business Update NeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business Update PR Newswire...
PR Newswire
<
1
2
...
>
Advertisement|Remove ads.
Latest NRSN News
ViewNeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS"
PR Newswire
NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALS
PR Newswire
NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease
PR Newswire
Advertisement|Remove ads.